| Added by | pmartino |
|---|---|
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: A multicenter study |
| Creator | Sgarbura et al. |
| Author | Olivia Sgarbura |
| Author | Martin Hübner |
| Author | Mohammad Alyami |
| Author | Clarisse Eveno |
| Author | Johan Gagnière |
| Author | Basile Pache |
| Author | Marc Pocard |
| Author | Naoual Bakrin |
| Author | François Quénet |
| Abstract | INTRODUCTION: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method used in patients with peritoneal cancer (PC) of primary or secondary origin. Intraperitoneal use of oxaliplatin raises concerns about toxicity, especially abdominal pain. The objective of this study was to assess the tolerance of PIPAC with oxaliplatin (PIPAC-Ox) in a large cohort of patients and to identify the risk factors for high grade toxicity, discontinuation of treatment and impaired survival. MATERIAL AND METHODS: This retrospective cohort study included all consecutive patients treated with PIPAC-Ox (92?mg/m2) in five centers specialized in the treatment of PC. The procedure was repeated every 6 weeks. Outcomes of interest were Common Terminology Criteria for Adverse Events (CTCAE), symptoms and survival (Kaplan-Meier). Univariate risk factors were included in a multinominal regression model to control for bias. RESULTS: Overall, 251 PIPAC-Ox treatments were performed in 101 patients (45 female) having unresectable PC of various origins: 66 colorectal, 15 gastric, 5 ovarian, 3 mesothelioma, 2 pseudomyxoma, 10 other malignancies (biliary, pancreatic, endocrine) respectively. The median PCI was 19 (IQR: 10-28). Postoperative abdominal pain was present in 23 patients. Out of the 9 patients with grade 3 abdominal pain, only 3 needed a change of PIPAC drug. CTCAE 4.0 toxicity grade 4 or higher was encountered in 16(15.9%) patients. The patients had a mean of 2.5 procedures/patient (SD?=?1.5). 50 subjects presented with symptom improvement. CONCLUSIONS: Oxaliplatin-based PIPAC appears to be a safe treatment that offers good symptom control and promising survival for patients with advanced peritoneal disease. |
| Publication | European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology |
| Date | May 09, 2019 |
| Journal Abbr | Eur J Surg Oncol |
| Language | eng |
| DOI | 10.1016/j.ejso.2019.05.007 |
| ISSN | 1532-2157 |
| Short Title | Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective |
| Library Catalog | PubMed |
| Extra | PMID: 31092362 |
| Tags | Aerosols, Aged, Antineoplastic Agents, clinic, Female, Humans, Infusions, Parenteral, Intraperitoneal chemotherapy, last, Male, Middle Aged, PBVOL, Peritoneal cancer, Peritoneal Neoplasms, PIPAC, Retrospective Studies |
| Date Added | 2019/05/22 - 08:48:07 |
| Date Modified | 2021/03/05 - 10:42:35 |
| Notes and Attachments | PubMed entry (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
